ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - טבליות מצופות פילם - venetoclax 10 mg - venetoclax

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - טבליות מצופות פילם - venetoclax 10 mg - venetoclax

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - טבליות מצופות פילם - venetoclax 100 mg - venetoclax

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - טבליות מצופות פילם - venetoclax 100 mg - venetoclax

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - טבליות מצופות פילם - venetoclax 50 mg - venetoclax

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - טבליות מצופות פילם - venetoclax 50 mg - venetoclax

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - aluminium hydroxide; magnesium hydroxide - תרחיף - aluminium hydroxide 175 mg / 5 ml; magnesium hydroxide 200 mg / 5 ml - ordinary salt combinations - ordinary salt combinations - antacid.

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - imiglucerase 200 u/vial - powder for solution for infusion - imiglucerase - for the long term enzyme replacement therapy for patients with a confirmed diagnosis of type 1 gaucher disease that results in one or more of the following conditions: - anemia , - thrombocytopenia , - bone disease , - hepatomegaly or splenomegaly.

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - agalsidase beta 5 mg/ml - powder for concentrate for infusion - agalsidase beta - long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease.

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - clopidogrel as hydrogen sulfate 300 mg - film coated tablets - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid